What is GRI Bio Profitability Rank?
GRI Bio has the Profitability Rank of 1. It has had trouble to make a profit.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:
1.
Operating Margin %
2.
Piotroski F-Score
3. Trend of the
Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank
GRI Bio's Operating Margin % for the quarter that ended in Mar. 2024 was %. As of today, GRI Bio's Piotroski F-Score is 9999.
Competitive Comparison of GRI Bio's Profitability Rank
For the Biotechnology subindustry, GRI Bio's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GRI Bio's Profitability Rank Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, GRI Bio's Profitability Rank distribution charts can be found below:
* The bar in red indicates where GRI Bio's Profitability Rank falls into.
GRI Bio Profitability Rank Calculation
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.
GRI Bio has the Profitability Rank of 1. It has had trouble to make a profit.
Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.
Profitability Rank is based on these factors:
1. Operating Margin %
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
GRI Bio's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
2. Piotroski F-Score
The zones of discrimination were as such:
Good or high score = 8 or 9
Bad or low score = 0 or 1
GRI Bio has an F-score of 9999. It is a bad or low score, which usually implies poor business operation.
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank
GRI Bio (GRI Bio) Business Description
Traded in Other Exchanges
N/A
Address
2223 Avenida De La Playa, Suite 208, La Jolla, CA, USA, 92037
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis.
Executives
| David Leslie Szekeres |
director |
C/O REGULUS THERAPEUTICS INC., 3545 JOHN HOPKINS COURT, SUITE 210, SAN DIEGO CA 92121 |
| Roelof Rongen |
director |
C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921 |
| Camilla V Simpson |
director |
20 ELAINE AVE., MILL VALLEY CA 94941 |
| Albert Agro |
officer: Chief Medical Officer |
828 RICHMOND STREET WEST, TORONTO A6 M6J 1C9 |
| Walter Marc Hertz |
director, 10 percent owner, officer: Chief Executive Officer |
2223 AVIENDA DE LA PLAYA, SUITE 208, LA JOLLA CA 92037 |
| Vipin Chaturvedi |
officer: Chief Scientific Officer |
2223 AVIENDA DE LA PLAYA, SUITE 208, LA JOLLA CA 92037 |
| Meenu Chhabra |
director |
C/O VALLON PHARAMCEUTICALS, INC., 100 N 18TH, STREET, SUITE 300, PHILADELPHIA PA 19103 |
| Joseph E Payne |
director |
10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121 |
| Leanne M. Kelly |
officer: Chief Financial Officer |
C/O VALLON PHARAMCEUTICALS, INC., 100 N 18TH STREET, SUITE 300, PHILADELPHIA PA 19103 |
| Marella Thorell |
director |
1226 CHARTER LANE, AMBLER PA 19002 |
| Arcturus Therapeutics Holdings Inc. |
10 percent owner |
10628 SCIENCE CENTER DRIVE, SUITE 250, SAN DIEGO CA 92121 |
| Penny Toren |
officer: SVP, Regul Affairs & Prog Mgmt |
C/O VALLON PHARMACEUTICALS, INC., 100 N. 18TH STREET, SUITE 300, PHILADELPHIA PA 19103 |
| Ofir Levi |
director |
C/O VALLON PHARMACEUTICALS, INC., 100 N. 18TH STREET, SUITE 300, PHILADELPHIA PA 19103 |
| Richard Ammer |
director, 10 percent owner |
C/O VALLON PHARMACEUTICALS, INC., 100 N. 18TH STREET, SUITE 300, PHILADELPHIA PA 19103 |
| Pharma Gmbh Salmon |
10 percent owner |
SANKT-JACOBS-STRASSE 90, CH-9002, BASEL V8 4052 |
GRI Bio (GRI Bio) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
:GRI has been successfully added to your